Peapod Lane Capital LLC Takes $1.27 Million Position in Metagenomi, Inc. (NASDAQ:MGX)

Peapod Lane Capital LLC purchased a new position in Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 351,213 shares of the company’s stock, valued at approximately $1,268,000. Peapod Lane Capital LLC owned approximately 0.94% of Metagenomi as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its position in shares of Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after purchasing an additional 7,256 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of Metagenomi in the third quarter valued at approximately $82,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Metagenomi by 209.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after acquiring an additional 92,468 shares in the last quarter. Geode Capital Management LLC grew its position in Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after acquiring an additional 173,796 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Metagenomi in the 3rd quarter valued at $33,000.

Metagenomi Price Performance

MGX stock opened at $2.39 on Thursday. The company’s 50-day moving average price is $3.11 and its two-hundred day moving average price is $2.71. Metagenomi, Inc. has a 12 month low of $1.61 and a 12 month high of $12.74.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MGX. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research note on Wednesday, November 20th. HC Wainwright upped their price objective on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Metagenomi currently has an average rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.